sub:assertion {
  d:DB04858 v:identifier "DB04858" ;
    v:namespace "drugbank" ;
    v:uri "http://bio2rdf.org/drugbank:DB04858" ;
    v:x-identifiers.org <http://identifiers.org/drugbank/DB04858> ;
    dv:drugbank-id "DB04858" ;
    dv:x-cas <http://bio2rdf.org/cas:27314-97-2> ;
    dv:x-chemspider <http://bio2rdf.org/chemspider:31132> ;
    dv:x-pubchemcompound <http://bio2rdf.org/pubchem.compound:33776> ;
    dv:x-pubchemsubstance <http://bio2rdf.org/pubchem.substance:10426937> ;
    dv:x-wikipedia <http://bio2rdf.org/wikipedia:Tirapazamine> ;
    dct:description "Tirapazamine (SR-4233) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Thus, tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective. As of 2006, tirapazamine is undergoing phase III testing in patients with head and neck cancer and gynecological cancer, and similar trials are being undertaken for other solid tumor types. [Wikipedia]"@en ;
    dct:identifier "drugbank:DB04858" ;
    dct:title "Tirapazamine"@en ;
    a dv:Drug ;
    rdfs:label "Tirapazamine [drugbank:DB04858]"@en ;
    rdfs:seeAlso <http://www.drugbank.ca/drugs/DB04858> .
}